These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26714208)

  • 1. Thrombolysis: A Critical First-Line Therapy with an Unfulfilled Potential.
    Gurewich V
    Am J Med; 2016 Jun; 129(6):573-5. PubMed ID: 26714208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke.
    Yang Y; Gu B; Xu XY
    Comput Biol Med; 2024 Mar; 171():108141. PubMed ID: 38367449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown.
    Gurewich V
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):749-753. PubMed ID: 31897763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.
    Pannell R; Li S; Gurewich V
    PLoS One; 2015; 10(3):e0122018. PubMed ID: 25811605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
    Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
    Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
    Gurewich V; Pannell R; Simmons-Byrd A; Sarmientos P; Liu JN; Badylak SF
    J Thromb Haemost; 2006 Jul; 4(7):1559-65. PubMed ID: 16839354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
    Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
    J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
    Maksimenko AV; Tischenko EG
    J Thromb Thrombolysis; 1999 Jun; 7(3):307-12. PubMed ID: 10373713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.
    Gelabert HA; Jimenez JC; Rigberg DA
    Ann Vasc Surg; 2007 Mar; 21(2):149-54. PubMed ID: 17349354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
    Badylak SF; Voytik SL; Henkin J; Burke SE; Sasahara AA; Simmons A
    Thromb Res; 1991 May; 62(3):115-26. PubMed ID: 1716378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study.
    Zhao L; Zhao Z; Chen X; Li J; Liu J; Li G;
    Heart Vessels; 2018 May; 33(5):507-512. PubMed ID: 29209778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
    Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
    Clase CM; Crowther MA; Ingram AJ; Cinà CS
    J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved.
    Gurewich V
    J Am Coll Cardiol; 2016 Nov; 68(19):2099-2106. PubMed ID: 27810050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of action and pharmacology of saruplase.
    Vermeer F
    Int J Clin Pract Suppl; 1998 Nov; 99():6-8. PubMed ID: 10344034
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
    Credo RB; Burke SE
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.